Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR1800015763Phase 4Recruiting
Phase 4, open-label, single-arm trial of dasatinib in acute lymphoblastic leukemia (ALL), sponsored by West China Hospital of Sichuan University. Primary endpoints: Complete remission rate, Overall survival and 1 more. Started Jan 2016; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR1800015763.